Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces

Publié le 16 août 2022 - Antimicrobial Agents and Chemotherapy

Auteurs : Delphine Lapaillerie, Cathy Charlier, Véronique Guyonnet-Dupérat, Emilie Murigneux, Henrique Fernandes, Fábio Martins, Rita Magalhães, Tatiana Vieira, Clémence Richetta, Frédéric Subra, Samuel Lebourgeois, Charlotte Charpentier, Diane Descamps, Benoît Visseaux, Pierre Weigel, Alexandre Favereaux, Claire Beauvineau, Frédéric Buron, Marie-Paule Teulade-Fichou, Sylvain Routier, Sarah Gallois-Montbrun, Laurent Meertens, Olivier Delelis, Sérgio Sousa, Vincent Parissi

Voir la publication sur HAL DOI

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent that has caused the current coronavirus disease (COVID) pandemic. Viral infection relies on the viral S (spike) protein/cellular receptor ACE2 interaction.